Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.95 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.95 |
| ▸ | HPGD | P15428 | 6/20 | 0.95 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.95 |
| ▸ | CA12 | O43570 | 2/20 | 0.95 |
| ▸ | CA1 | P00915 | 2/20 | 0.95 |
| ▸ | CA2 | P00918 | 2/20 | 0.95 |
| ▸ | CA7 | P43166 | 2/20 | 0.95 |
| ▸ | CA9 | Q16790 | 2/20 | 0.95 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.95 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.95 |
| ▸ | CA4 | P22748 | 1/20 | 0.95 |
| ▸ | CA6 | P23280 | 1/20 | 0.95 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.95 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.65 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL4488987 | 0.97 | ALDH1A1 (0.90) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL17156443 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29606432 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1509155 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL1967 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29362663 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL29360246 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8433746 | 0.97 | ALDH1A1 (1.00) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL971594 | 0.95 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 | |
| Salicylic Acid SCHEMBL8721348 | 0.95 | ALDH1A1 (0.95) | ALDH1A1KDM4EHPGDSMN1; SMN2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 376 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112535763-B | Controllable fluorine slow-release hydroxyapatite porous microsphere carrier material and preparation method thereof | 天津工业大学 | 2023-06-06 | — | — | CN | claimed |
| CN-112535763-A | Controllable fluorine slow-release hydroxyapatite porous microsphere carrier material and preparation method thereof | 天津工业大学 | 2021-03-23 | — | — | CN | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| CN-106456662-A | Compositions of pentosan polysulfate for oral administration and methods of use thereof | 奥利金制药公司 | 2017-02-22 | — | — | CN | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| US-9125919-B2 | Acne treatment powder foundation | EI LLC (US) | 2015-09-08 | — | — | US | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| CN-102976996-B | Atorvastatin semi strontium salt polymorphic form, its preparation and the application as HMG-CoA enzyme inhibitors | XIAJIANG HEMEI PHARMACEUTICAL CO., LTD. (CN) | 2015-08-19 | — | — | CN | claimed |
| CN-102976997-A | Polymorphic substance of atorvastatin semi-strontium salt as well as preparation method and application of polymorphic substance as HMG-CoA (Hydroxy Methylglutaryl Coenzyme A) enzyme inhibitor | TIANJIN HEMAY BIO TECH CO LTD | 2013-03-20 | — | — | CN | claimed |
| CN-102976996-A | Polymorphic substance of atorvastatin semi-strontium salt as well as preparation method and application of polymorphic substance as HMG-CoA (Hydroxy Methylglutaryl Coenzyme A) enzyme inhibitor | TIANJIN HEMAY BIO TECH CO LTD | 2013-03-20 | — | — | CN | claimed |
| US-20070292535-A1 | Strontium compositions and methods of treating arthritic and or osteoporitic conditions | TRX PHARMACEUTICALS, LLC | 2007-12-20 | — | — | US | claimed |
| EP-1758652-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | claimed |
| EP-1758653-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | Osteologix A/S (DK) | 2007-03-07 | — | — | EP | claimed |
| EP-1745791-A2 | Treating cartilage/bone conditions with water-soluble strontium salts | Osteologix A/S (DK) | 2007-01-24 | — | — | EP | claimed |
| WO-2007003200-A2 | HIGH YIELD SYNTHESIS METHODS FOR PRODUCING ORGANIC SALTS OF STRONTIUM | OSTEOLOGIX A/S (DK) | 2007-01-11 | — | — | WO | claimed |
| WO-2005123193-A2 | TREATMENTS COMPRISING STRONTIUM FOR RHEUMATIC AND ARTHRITIC DISEASES AND PAIN | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123130-A2 | IMPROVED TREATMENTS OF RHEUMATIC AND ARTHRITIC DISEASES COMPRISING COMBINATIONS OF A 5-LIPOXYGENASE INHIBITOR | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| WO-2005123192-A2 | IMPROVING PAIN TREATMENT WITH STRONTIUM COMBINATIONS | OSTEOLOGIX A/S (DK) | 2005-12-29 | — | — | WO | claimed |
| US-5449509-A | Desensitizing dentifrice | BEECHAM GROUP P.L.C. (GB) | 1995-09-12 | — | — | US | claimed |
| US-3964255-A | Method of inflating an automobile passenger restraint bag | SPECIALTY PRODUCTS DEVELOPMENT CORPORATION (US) | 1976-06-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | ALDH1A1 3725/4885KDM4E 4162/4885HPGD 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.